Vu Le

Array ( [id] => 18056501 [patent_doc_number] => 20220387587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => HUMANIZED ANTI-CD40 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/818188 [patent_app_country] => US [patent_app_date] => 2022-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27034 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17818188 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18360371 [patent_doc_number] => 20230141962 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => COMPOSITIONS FOR PREVENTING OR TREATING VIRAL AND OTHER MICROBIAL INFECTIONS [patent_app_type] => utility [patent_app_number] => 17/817578 [patent_app_country] => US [patent_app_date] => 2022-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17817578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20413207 [patent_doc_number] => 12496470 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-16 [patent_title] => Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 17/863864 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 6 [patent_no_of_words] => 48199 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 1308 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17863864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19809539 [patent_doc_number] => 12240910 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-04 [patent_title] => Anti-C-C motif chemokine receptor 8 (CCR8) antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/864074 [patent_app_country] => US [patent_app_date] => 2022-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 58 [patent_figures_cnt] => 68 [patent_no_of_words] => 54269 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17864074 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18467083 [patent_doc_number] => 20230201364 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => ANTIBODY CONJUGATES AND MANUFACTURE THEREOF [patent_app_type] => utility [patent_app_number] => 17/861176 [patent_app_country] => US [patent_app_date] => 2022-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63889 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17861176 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18168697 [patent_doc_number] => 20230035308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => ACTIVATABLE MONOMERIC CYTOKINE-SINGLE CHAIN (SC) FC FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/810422 [patent_app_country] => US [patent_app_date] => 2022-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11481 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17810422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146520 [patent_doc_number] => 20230020377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => ANTI-CTLA-4 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/848983 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18146520 [patent_doc_number] => 20230020377 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => ANTI-CTLA-4 ANTIBODY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/848983 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 96080 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17848983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18109598 [patent_doc_number] => 20230002478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-05 [patent_title] => METHODS AND COMPOSITIONS RELATING TO COVID ANTIBODY EPITOPES [patent_app_type] => utility [patent_app_number] => 17/847104 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17847104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18170317 [patent_doc_number] => 20230036928 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-02 [patent_title] => ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE [patent_app_type] => utility [patent_app_number] => 17/843812 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058029 [patent_doc_number] => 20220389115 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => Methods of Treating Cancer with an Anti-CD39 Antibody [patent_app_type] => utility [patent_app_number] => 17/829480 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24399 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17837798 [patent_doc_number] => 20220275103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => ANTI-CD300C MONOCLONAL ANTIBODY AND BIOMARKER THEREOF FOR PREVENTING OR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/746569 [patent_app_country] => US [patent_app_date] => 2022-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -34 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17746569 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18058308 [patent_doc_number] => 20220389394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => METHODS OF USING FLT3L-Fc FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 17/744515 [patent_app_country] => US [patent_app_date] => 2022-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 236209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17744515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18064486 [patent_doc_number] => 20220395573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-15 [patent_title] => High Concentration Bispecific Antibody Formulations [patent_app_type] => utility [patent_app_number] => 17/725755 [patent_app_country] => US [patent_app_date] => 2022-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -49 [patent_words_short_claim] => 144 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17960099 [patent_doc_number] => 20220340679 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => CO-INHIBITION OF CD47/SIRPalpha BINDING AND NEDD8-ACTIVATING ENZYME E1 REGULATORY SUBUNIT FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/719122 [patent_app_country] => US [patent_app_date] => 2022-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36643 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17719122 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17945832 [patent_doc_number] => 20220332849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => Stabilized Formulations Containing Anti-MUC16 x Anti-CD3 Bispecific Antibodies [patent_app_type] => utility [patent_app_number] => 17/711800 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40146 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19473901 [patent_doc_number] => 12103977 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-01 [patent_title] => Trispecific antibody targeting CD79b, CD20, and CD3 [patent_app_type] => utility [patent_app_number] => 17/702282 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 48 [patent_figures_cnt] => 100 [patent_no_of_words] => 100442 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702282 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19667550 [patent_doc_number] => 12180278 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-31 [patent_title] => Antibody targeting CD22 and CD79B [patent_app_type] => utility [patent_app_number] => 17/702042 [patent_app_country] => US [patent_app_date] => 2022-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 38536 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17702042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20302466 [patent_doc_number] => 12448444 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-21 [patent_title] => Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/701573 [patent_app_country] => US [patent_app_date] => 2022-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 30 [patent_no_of_words] => 95984 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 252 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701573 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339328 [patent_doc_number] => 12049506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Therapeutic binding molecules [patent_app_type] => utility [patent_app_number] => 17/697041 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 48 [patent_no_of_words] => 30075 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 213 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697041 [rel_patent_id] =>[rel_patent_doc_number] =>)